Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Salivary Gland Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 9Nivolumab 4Magnetic Resonance Spectroscopy 3spartalizumab 2Ipilimumab 2Gemcitabine 2Fluorodeoxyglucose F18 2FAPI-46 2Drug Therapy 2Cisplatin 2zenocutuzumab 1venetoclax 1ulixertinib 1trametinib 1tislelizumab 1seribantumab 1rovalpituzumab tesirine 1pazopanib 1neratinib 1margetuximab 1lenvatinib 1entrectinib 1durvalumab 1cobimetinib 1cemiplimab 1budigalimab 1bemarituzumab 1atezolizumab 1alectinib 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × neratinib × Head & Neck × Clear all
NCT06519110 2024-07-25

CVL009-C2001

Convalife (Shanghai) Co., Ltd.

Phase 2 Not yet recruiting
60 enrolled
GastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Salivary Gland Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡